@article{dafac625f7de424a96a6066f17b72100,
title = "The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: The D:A:D study",
abstract = "We assessed whether fasting modifies the prognostic value of these measurements for the risk of myocardial infarction (MI). Analyses used mixed effect models and Poisson regression. After confounders were controlled for, fasting triglyceride levels were, on average, 0.122 mmol/L lower than nonfasting levels. Each 2-fold increase in the latest triglyceride level was associated with a 38% increase in MI risk (relative rate, 1.38; 95% confidence interval, 1.26-1.51); fasting status did not modify this association. Our results suggest that it may not be necessary to restrict analyses to fasting measurements when considering MI risk. {\textcopyright} The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.",
keywords = "antilipemic agent, antiretrovirus agent, triacylglycerol, adult, article, bisexuality, body mass, cardiovascular disease, controlled study, demography, diabetes mellitus, diet restriction, ethnic difference, female, heart infarction, hepatitis C, Hepatitis C virus, human, Human immunodeficiency virus infected patient, Human immunodeficiency virus infection, hypertension, major clinical study, male, male homosexual, prediction, priority journal, prognosis, risk factor, sex difference, smoking",
author = "D.A. Kamara and S.W. Worm and P. Reiss and M. Rickenbach and A. Phillips and O. Kirk and {D'Arminio Monforte}, A. and M. Bruyand and M. Law and {De Wit}, S. and C.J. Smith and C. Pradier and J. Lundgren and C. Sabin and Ferran Torres",
note = "Export Date: 17 February 2022 CODEN: JIDIA Correspondence Address: Kamara, D.A.; Research Department of Infection and Population Health, Rowland Hill St, London NW3 2PF, United Kingdom; email: d.kamara@ucl.ac.uk Funding details: CT94-1637, CT97-2713 Funding details: FIS 99/0887 Funding details: 5U01AI042170-10, 5U01AI046362-03, FIPSE 3171/00 Funding details: CURE/97-46486 Funding details: National Institutes of Health, NIH, U01-AI069907 Funding details: U.S. Food and Drug Administration, FDA Funding details: National Institute of Allergy and Infectious Diseases, NIAID Funding details: amfAR, The Foundation for AIDS Research Funding details: Abbott Laboratories Funding details: Bristol-Myers Squibb, BMS Funding details: Pfizer Funding details: GlaxoSmithKline, GSK Funding details: Merck Funding details: Roche Funding details: Gilead Sciences Funding details: Boehringer Ingelheim Funding details: Merck Sharp and Dohme, MSD Funding details: Cilag Funding details: Gilead UK and Ireland Corporate Contributions Funding details: European Commission, EC Funding details: Department of Health and Ageing, Australian Government Funding details: Schweizerischer Nationalfonds zur F{\"o}rderung der Wissenschaftlichen Forschung, SNF Funding details: University of New South Wales, UNSW Funding details: Agence Nationale de Recherches sur le Sida et les H{\'e}patites Virales, ANRS Funding details: Fifth Framework Programme, FP5, QLK2-2000-00773 Funding text 1: This work was supported by the Oversight Committee for The Evaluation of Metabolic Complications of HAART, a collaborative committee with representation from academic institutions, the European Agency for the valuation of Medicinal Products, the Food and Drug Administration, the patient community, and all pharmaceutical companies with licensed anti-HIV drugs in the US market: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, and Hoffman-LaRoche. The AIDS Therapy Evaluation Project Netherlands (ATHENA) was supported by the Health Insurance Fund Council, Amstelveen, the Netherlands (grant CURE/97-46486). The Aquitaine Cohort was supported by a grant from the Agence Nationale de Recherches sur le SIDA (Action Coordonn{\'e}e no. 7, Cohortes). The Australian HIV Observational Database is funded as part of the Asia Pacific HIV Observational Database, a program of the Foundation for AIDS Research, and is supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (grant U01-AI069907), and by unconditional grants from Merck Sharp & Dohme, Gilead, Bristol-Myers Squibb, Boehringer Ingelheim, Roche, Pfizer, GlaxoSmithKline, and Janssen-Cilag. The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, University of New South Wales. The Barcelona Antiretroviral Surveillance Study (BASS) is supported by the Fondo de Investigaci{\'o}n Sanitaria (grant FIS 99/0887) and Fundaci{\'o}n para la Investigaci{\'o}n y la Prevenci{\'o}n del SIDA en Espan{\~a} (grant FIPSE 3171/00).The Terry Beirn Community Programs for Clinical Research on AIDS is supported by the NIAID (grants 5U01AI042170-10 and 5U01AI046362-03). The EuroSIDA study was supported by the BIOMED 1 (grant CT94-1637) and BIOMED 2 (grant CT97-2713) programs and the Fifth Framework program (grant QLK2-2000-00773) of the European Commission and by Bristol-Myers Squibb, GlaxoSmithKline, Boehringer Ingelheim, and Roche. The Italian Cohort Naive to Antiretrovirals (ICONA Foundation) was supported by unrestricted educational grants from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Pfizer, and Janssen-Cilag. The Swiss HIV Cohort Study was supported by a grant from the Swiss National Science Foundation. References: Morse, C.G., Kovacs, J.A., Metabolic and skeletal complications of HIV infection: The price of success (2006) Journal of the American Medical Association, 296 (7), pp. 844-854. , http://jama.ama-assn.org/cgi/reprint/296/7/844, DOI 10.1001/jama.296.7.844; Nordestgaard, B.G., Benn, M., Schnohr, P., Tybjaerg-Hansen, A., Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women (2007) Journal of the American Medical Association, 298 (3), pp. 299-308. , http://jama.ama-assn.org/cgi/reprint/298/3/299, DOI 10.1001/jama.298.3.299; Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S.M., Gudnason, V., Triglycerides and the risk of coronary heart disease: 10 158 Incident cases among 262 525 participants in 29 Western prospective studies (2007) Circulation, 115 (4), pp. 450-458. , DOI 10.1161/CIRCULATIONAHA.106.637793, PII 0000301720070130000007; Di, A.E., Sarwar, N., Perry, P., Major lipids, apolipoproteins, and risk of vascular disease (2009) JAMA, 302, pp. 1993-2000; Ridker, P.M., Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: Do we need to revisit the oral triglyceride tolerance test? (2008) Clinical Chemistry, 54 (1), pp. 11-13. , http://www.clinchem.org/cgi/reprint/54/1/11, DOI 10.1373/clinchem.2007.097907; Stalenhoef, A.F., De, G.J., Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL (2008) Curr Opin Lipidol, 19, pp. 355-361; Warnick, G.R., Nakajima, K., Fasting versus nonfasting triglycerides: Implications for laboratory measurements (2008) Clinical Chemistry, 54 (1), pp. 14-16. , http://www.clinchem.org/cgi/reprint/54/1/14, DOI 10.1373/clinchem.2007.098863; Eberly, L.E., Stamler, J., Neaton, J.D., Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease (2003) Archives of Internal Medicine, 163 (9), pp. 1077-1083. , DOI 10.1001/archinte.163.9.1077; Mora, S., Rifai, N., Buring, J.E., Ridker, P.M., Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events (2008) Circulation, 118, pp. 993-1001; Bansal, S., Buring, J.E., Rifai, N., Mora, S., Sacks, F.M., Ridker, P.M., Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women (2007) Journal of the American Medical Association, 298 (3), pp. 309-316. , http://jama.ama-assn.org/cgi/reprint/298/3/309, DOI 10.1001/jama.298.3.309; Friis-Moller, N., Sabin, C.A., Weber, R., Combination antiretroviral therapy and the risk of myocardial infarction (2003) N Engl J Med, 349, pp. 1993-2003; Toth, P.P., Maki, K.C., (2008) Practical Lipid Management: Concepts and Controversies, , Oxford: Wiley-Blackwell; Wilhelm, M.G., Cooper, A.D., Induction of atherosclerosis by human chylomicron remnants: A hypothesis (2003) J Atheroscler Thromb, 10, pp. 132-139; Stein, J.H., Merwood, M.A., Bellehumeur, J.B., McBride, P.E., Wiebe, D.A., Sosman, J.M., Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection (2005) Arteriosclerosis, Thrombosis, and Vascular Biology, 25 (2), pp. 399-405. , DOI 10.1161/01.ATV.0000152233.80082.9c; Ginsberg, H.N., New perspectives on atherogenesis: Role of abnormal triglyceride-rich lipoprotein metabolism (2002) Circulation, 106 (16), pp. 2137-2142. , DOI 10.1161/01.CIR.0000035280.64322.31",
year = "2011",
month = aug,
doi = "10.1093/infdis/jir329",
language = "English",
volume = "204",
pages = "521--525",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
number = "4",
}
